

Indices	CMP	%1D
Sensex	33342	0.71
Nifty	10283	0.67
BSE-Midcap	16673	1.03
BSE-Smallcap	17605	0.81
SGX Nifty	10289	-0.12

Sector	CMP	%1D
Capital Goods	18236	0.45
Realty	2362	3.70
Consumer Dur	20336	1.47
Metal	14248	1.80
Oil & Gas	15714	0.34
Teck	6064	-1.1

Index	FY17	FY18E	FY19E
Sensex EPS	1370	1550	1948
P/E	24	22	17
Nifty EPS	434	514	617
P/E	24	20	17

FII Trading activity in cash Rs Cr			
Date 17 November	Net	MTD	FY17
FII	1276	-8872	-66328
DII	1466	4703	77009

Global Indices	Current Value	%1D
DowJones	23358	-0.43
Nasdaq	6782	-0.15
DAX	12993	-0.41
Nikkei 225	22300	-0.43
FTSE 100	7380	-0.08
Hang Seng	29176	-0.08
Shanghai	3395	-0.10
Straits Times	3382	0.01

Forex Rate		
	Price	Change%
USD/INR	65.11	-0.41%
EUR/INR	76.85	-0.09%
GBP/INR	85.95	-0.36%
JPY/INR	57.80	0.05%

G-Sec Yield		
	Price	Change%
1yr Bond Yield	6.37	-0.23
10yr Bond Yield	7.04	-0.21

Market Outlook

Indian markets likely to open on a flat positive note on the back of global market sentiments. Tracking the momentum, Markets should hold above 10180 level which acts as a major support and resistance is near 10380 in near terms. Investors are advised to tread with caution but at the same time remain long on the index for next possible target of 10600.

Top Domestic News

- Logistics Sector To Get Infrastructure Status-Fin Min Has Given The Nod To Give The Logistics Sector Infrastructure Status. The Move Eases Investment Regulations In The Logistics Sector. The Move Enables Logistics Sector To Get Cheaper & Longer Term Loans .Banks To Give Priority To Logistics Sector While Lending Transportation, Warehouse, Logistics Parks Segments Included In Logistics Sector .A Separate Dept For Logistics Formed U/Commerce & Ind Min For Dvpt Of Logistics Sector
- BSE Sensex Changes- Yes Bank and IndusInd Bank will be included in the index from December 18 Lupin and Cipla will be excluded from the index from December 18
- Biocon Gets Establishment Inspection Report For May 25-June 3 Inspection By US FDA
- Aseptic Drug Product Facility's Inspection Is Closed By US FDA
- AstraZeneca Arm, AstraZeneca AB Gets US FDA Nod For Monoclonal Antibody, Benralizumab Injectable
- Teva Gets US FDA Nod For Darunavir Tablets
- L&T Construction to build Mumbai Trans Harbour Link Order valued at Rs.8,650 Crore
- Strides Shasun divests India brand business to Eris Lifescience
- Divis received an Establishment Inspection Report (EIR) from US-FDA for our Unit-II, as closure of audit by FDA
- Mayur Uniquoters says Buyback up to 4,50,000 fully paid up Equity Shares for an amount Rs.24.7 cr
- Moody's Investors Service - withdraws rating of Reliance Communications and its Senior Secured Notes
- SMS Pharma completed its Fifth US Food and Drug Administration (US FDA) inspection for its Manufacturing facility - Unit-II, located
- Promoters maybe looking to exit Vadilal, looking at a valuation of rs600cr
- Axis Bank-led lenders file for insolvency proceedings against Seven Hills Whirlpool, Voltas, Bajaj Electricals in focus - GST rate may be cut down to 18% vs 28%

Global News

Wall Street ended the week on a sour note on Friday, with major indexes slipping modestly as investors weighed the fate of the Republicans' tax overhaul plan. The Dow Jones Industrial Average fell 100.12 points, or 0.43%, to 23,358.24, the S&P 500 lost 6.79 points, or 0.26%, to 2,578.85 and the Nasdaq Composite dropped 10.50 points, or 0.15%, to 6,782.79, Reuters reported. Asian shares started the week on the back foot on Monday, pressured by a retreat on Wall Street amid tax reform uncertainty while the euro skidded after German coalition talks hit an impasse. MSCI's broadest index of Asia-Pacific shares outside Japan was nearly flat in early trade. Australian shares were down 0.2%, while Japan's Nikkei stock average was 0.1% lower, Reuters reported.

NSE Top Gainers

Script	LTP	%1D
HDFC	1702.00	2.27
CIPLA	605.75	2.18
MARUTI	8337.00	2.12
TATAMOTOR	421.70	2.00
ICICIBANK	324.55	1.76

NSE Top Losers

Script	LTP	%1D
TECHM	484.00	-3.18
INFY	965.50	-2.32
BOSCHLTD	18962	-1.54
TCS	2708.20	-1.40
HCLTECH	840.20	-1.37

BSE Top Gainers

Script	LTP	%1D
RENUKA	17.51	13.85
GATI	131.25	9.83
JUBILANT	675.90	9.51
ADANIANT	156.40	8.01
POLARIS	356.75	7.39

BSE Top Losers

Script	LTP	%1D
VIDEOIND	14.25	-2.73
TECHM	485.05	-2.71
GPPL	131.00	-2.64
BBTC	1458.65	-2.54
PAGEIND	23534.55	-2.51

Technical View



Bank Nifty has opened with a gap up and held on the momentum and made a fresh new high. Bank Nifty has today given a break out from a Decending Channel Pattern. The target for this pattern is 26786.5. But it is adviced to watch 25630 & 26180 as both are strong resistance levels. The gap ups, the 13 EMA is above 21 EMA, MACD is also giving a buy signal and the RSI is not in over bought zone. All of them indicate a strong up move rally.

Msearch

MEHTA



Disclaimer: The views expressed / recommendations made in this report are based on Technical Analysis techniques and could be at variance with the company's / group's views based on fundamental research. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options another derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MEHTA EQUITIES LTD, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MEHTA EQUITIES LTD. The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEHTA EQUITIES LTD to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India
Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email: info@mehtagroup.in, Website: www.mehtagroup.in